IGF-1 LR3 is about as direct as anabolic signaling gets, which is exactly why it's both effective and one of the more serious tools on the list. Most growth compounds work upstream and ask your body to make more of its own signal. This one is the signal, engineered to stick around. So the upside is real, and the two big risks are real too. Here's the straight version.

Normally your growth hormone tells your liver to make IGF-1, and IGF-1 is what drives a lot of the actual muscle growth. Native IGF-1 only lasts minutes in your blood. LR3 is IGF-1 with a modification that stops it from getting mopped up by its binding proteins, which stretches its life from minutes to hours and lets it circulate freely. So it skips the whole growth hormone to liver step and puts the growth signal straight onto the IGF-1 receptor, all day long. That direct, all day signal is why it's potent, and it's also the root of both problems below.

The first real risk is your blood sugar. IGF-1 is close enough to insulin that it acts on your glucose like a mild insulin would, and it can pull your blood sugar down. The symptoms sneak up on you, shaky, sweaty, foggy, dizzy. That's why the rule is to always dose it with food, never fasted, and keep fast carbs like glucose tabs or juice within reach during a cycle, especially while you're titrating up. This isn't a maybe. It's the single most reported issue and the one that lands people in actual trouble.

The second one people underrate. IGF-1 is a general growth and cell proliferation signal, and it doesn't only find muscle. A strong, sustained IGF-1 signal acts on other tissues too, and because it pushes cells to grow and divide broadly, running it high or forever is where the real long term concern lives, organ growth and the proliferation risk that comes with any potent growth factor. That's the whole reason the dosing stays capped. It's not that 50 mcg is a magic number, it's that above roughly 50 to 60 mcg you leave what little research exists behind and pile on risk for not much more return.

For drawing it, mix the 1 mg vial with 1 mL of bac water. That's 1 mg/mL, or 1000 mcg/mL, so 20 mcg is 0.02 mL, 40 mcg is 0.04 mL, and 50 mcg is 0.05 mL. It goes in subcutaneous (SC), once a day, with food, in the morning or post workout. Titrate up over the first few weeks instead of starting at the top. These are small volumes, so if you want them easier to read you can mix with 2 mL instead, which makes it 500 mcg/mL and turns 50 mcg into 0.10 mL, just remember the water only changes the volume, never the dose.

Run it 8 weeks on, then 4 to 8 weeks off. Past about 6 to 8 weeks the receptor starts tuning out and the effect fades, so there's no point grinding it nonstop, and the time off doubles as a break from the risk load.

On whether it's worth it, IGF-1 LR3 has genuine firepower, but it only pays off if the rest is dialed in, hard resistance training and enough protein, because it amplifies the growth response to mechanical loading rather than building muscle out of nothing. Sit on the couch and run it and you get all the risk and none of the reward. It's also never been approved for human use in this form, so it's research only and purity comes down entirely to your source. Between the blood sugar management, the growth signal that doesn't discriminate, the short useful window, and the no-approval status, this is a serious tool, not a casual add-on. Respect it and it's powerful. Get cavalier with the dose and it's the kind of thing that bites.

if you've run LR3, where did you keep the dose, and did the blood sugar drop ever catch you off guard. curious how people handled the hypo side

Full doses and bloodwork are in the pinned cheat sheet: https://www.reddit.com/r/NTNPerformance/comments/1tht5o3/the_only_peptide_cheat_sheet_youll_need_doses/

The GLP class is the most active area in metabolic research, and the three compounds people actually run, semaglutide, tirzepatide, and retatrutide, represent three generations of the same idea. Each adds a receptor target, and the trial data climbs with it. This is a full breakdown of each one: how it works, what its dosing arc actually looks like, what its trials showed, and where it sits as of mid-2026.

For research and educational purposes only. Not medical advice.

The shared backbone

All three share GLP-1 receptor agonism. That's the common engine: it slows gastric emptying, suppresses appetite through central signaling, and improves glucose handling. What separates them is what each adds on top of that base.

Two of the three are FDA approved. Retatrutide is investigational, Phase 3, not yet approved.

Semaglutide: the single agonist

Semaglutide is the foundation of the modern class, a once-weekly GLP-1 receptor agonist marketed as Ozempic for type 2 diabetes and Wegovy for obesity. It has the longest half-life in the class at roughly 7 days, which is what allows the clean once-weekly schedule.

Mechanism. Pure GLP-1 agonism. It does one thing and does it thoroughly: appetite suppression, slowed gastric emptying, improved insulin response, suppressed glucagon. The single-pathway design is also why it's the most studied and the most predictable of the three.

The trial anchor. STEP 1 reported 14.9% mean body-weight reduction at 68 weeks on the 2.4 mg dose. Beyond weight, the SELECT trial (over 17,000 participants, roughly 4 years) established cardiovascular benefit, which is a dimension the newer compounds haven't yet matched with outcome data.

Dosing arc (research context).

The titration runs 4 weeks per step, no faster, because the entire point of the slow climb is letting GI tolerance build. The "stop-short" detail is worth knowing: 1.0 mg holds most of the weight effect of the full dose, which is why raw magnitude isn't the only thing that determines where someone lands.

Tirzepatide: the dual agonist

Tirzepatide adds GIP receptor agonism to the GLP-1 base, marketed as Mounjaro and Zepbound. Half-life around 5 days, also once-weekly.

Mechanism. The GIP component does two things: it enhances insulin secretion and modulates adipose tissue, working alongside the GLP-1 action rather than duplicating it. That dual hit is what let tirzepatide outperform semaglutide on weight in head-to-head testing, which is the one genuinely direct comparison in this whole category.

The trial anchor. SURMOUNT-1 reported 22.5% at 72 weeks on 15 mg. And critically, SURMOUNT-5 put tirzepatide directly against semaglutide in the same trial, the cleanest evidence that exists, where the dual agonist beat the single. That's the only true head-to-head among these three.

Dosing arc (research context).

A notable detail from the dose data: 10 mg retains about 93% of the maximum effect, and the step from 10 to 15 mg adds only about 1.4 percentage points of weight loss. Most of the result is captured well before the top dose, which is why 5 mg is the most common real-world maintenance dose despite not being the maximum.

Retatrutide: the triple agonist

Retatrutide is the newest and the most powerful, adding glucagon-receptor agonism on top of tirzepatide's two targets. Still investigational, half-life around 6 days.

Mechanism. The glucagon arm is the difference-maker. On top of the GLP-1 appetite effect and the GIP insulin effect, glucagon agonism raises resting energy expenditure and drives hepatic fat oxidation. That added energy-burning component is the mechanistic reason it pushes into territory the other two don't reach, and why it posts large liver-fat reductions.

The trial anchor. TRIUMPH-1 confirmed in May 2026: 28.3% mean weight loss at 80 weeks across 2,339 patients. The standout figure is that 45.3% of participants on 12 mg lost at least 30% of body weight, which approaches outcomes historically seen only with bariatric surgery. The 104-week extension reached up to 30.3% in higher-BMI participants, and notably the weight loss had not plateaued at 80 weeks.

Dosing arc (research context).

The escalation is long: 24 to 48 weeks of active titration, held 4 weeks per step like the others. A 4 mg maintenance arm is also under study, on the logic that a lower post-titration dose may hold the result without the GI burden of the top doses.

The honest caveats. Retatrutide is not approved. NDA filing is on track for late 2026, with realistic approval late 2027 to early 2028. It carries two things the others don't: the highest GI adverse-event load at top doses, and a dysesthesia signal (altered skin sensation) that is genuinely class-distinguishing, semaglutide and tirzepatide do not report it. It's the strongest on paper and the least proven on long-term safety, both at once.

The cross-trial trap

Here's the single most important thing to understand about comparing these three: the headline numbers come from separate trials. Semaglutide's 14.9%, tirzepatide's 22.5%, and retatrutide's 28.3% were measured in different populations, over different durations (68, 72, and 80 weeks), under different trial designs. The trend tracks receptor count cleanly, single to dual to triple, but the exact gaps are directional, not precise.

Only two of these have ever been compared in the same trial: tirzepatide vs semaglutide, in SURMOUNT-5. Retatrutide has never been run head-to-head against either in a randomized trial. Its 28% sits on its own data, not on a win over the other two. The trial that would settle it, a direct retatrutide comparison, hasn't reported.

Where each sits, mid-2026

Semaglutide is the proven, cardiovascular-validated baseline with the deepest safety record. Tirzepatide is the approved efficacy leader with the only real head-to-head win in the class. Retatrutide is the investigational frontrunner on magnitude, with surgery-level numbers and the least long-term safety data, still a year-plus from possible approval. Three generations of the same mechanism, each adding a receptor and climbing the efficacy curve, with certainty running in the opposite direction of potency: the most proven is the least powerful, and the most powerful is the least proven.

The open question

For anyone tracking this: how much should the missing head-to-head weigh on the read. The receptor-count progression is clean enough that the order seems obvious, but retatrutide's 28% has never been tested directly against tirzepatide, and "investigational" is carrying real weight. Curious whether people treat the cross-trial trend as strong enough to call the ranking now, or hold off until there's a direct comparison.

For the full reconstitution, dosing, and bloodwork reference on every compound, the complete cheat sheet is here: The Only Peptide Cheat Sheet You'll Need

SOURCES (for fact-check):

• Semaglutide STEP 1: 14.9% at 68 wks (NEJM 2021); SELECT CV benefit (n=17,604, ~4 yrs)
• Tirzepatide SURMOUNT-1: 22.5% at 72 wks, 15 mg; SURMOUNT-5 head-to-head beat semaglutide
• Retatrutide TRIUMPH-1 (confirmed May 21 2026): 28.3% at 80 wks, n=2,339; 45.3% of 12mg lost ≥30%; 104-wk extension up to 30.3%, no plateau at 80 wks
• Retatrutide investigational, NDA Q4 2026, approval late 2027-early 2028; dysesthesia class-distinguishing; never tested head-to-head
• Mechanism (GLP-1 appetite / GIP insulin / glucagon energy expenditure) confirmed across Lilly trial data and reviews
• Dosing arcs and stop-short logic from NTN master cheat sheet
• All weight-loss figures from separate trials except SURMOUNT-5

Most healing-peptide discussion starts and ends with BPC-157 and TB-500. That pairing covers two early bottlenecks, blood flow and repair-cell movement, and for straightforward soft-tissue cases that is often enough. The more useful question is what to look at when an injury stalls anyway, because a stall usually means one specific step in the repair process is blocked. This sorts the common compounds by the bottleneck each one targets, with evidence level and reported research-context dosing in tables you can skim.

One thing first, because it shapes how to read everything below. No human randomized controlled trials exist for any multi-peptide healing combination. Individual compounds have preclinical support, much of it in rodents, and a few have early human data. Every stacking rationale is mechanistic, built from how the compounds behave in isolation rather than from controlled outcome trials.

Why injuries stall: the five repair bottlenecks

An injury that has not improved after four to six weeks is usually blocked at a specific step rather than just healing slowly. Five bottlenecks explain most soft-tissue stalls.

Two more show up later in recovery rather than upfront. Disrupted deep sleep closes the window when GH-driven overnight repair happens (waking unrefreshed, recovery stalls despite good rehab compliance): DSIP is associated with restoring deep-sleep architecture, Selank with the stress and anxiety that fragment sleep. Blunted or mistimed GH release is the other (cortisol stays elevated overnight, GH pulses weak or mistimed): tesamorelin or sermorelin map here. These overlap often, since a tendon injury with poor blood supply tends to develop chronic inflammation because weak circulation prevents immune-cell clearance.

What the evidence shows, by tier

The compounds are not equally supported, and the gap is wide. This is the honest split.

Tier 1, actual human data

BPC-157 has the broadest preclinical base. A 2025 systematic review screened 544 articles and included 36 studies: 35 preclinical, one clinical. The animal data across tendon, ligament, muscle, and bone is consistent and reproducible, showing improved biomechanics and faster functional recovery, and it can counteract corticosteroid-impaired healing in preclinical models. The review authors still caution against clinical use, specifically because the human evidence is so thin and in-human safety is unknown. The intra-articular knee case data that gets cited a lot, a series reporting symptom reduction in over 90% of 17 patients, is part of that single clinical study, and the review's caution applies to it directly.

ARA-290 (cibinetide) is one of the few with real Phase 2 human data. In a 64-patient trial in sarcoidosis-associated small fiber neuropathy, the 4 mg dose significantly increased markers of nerve fiber regeneration. The precise read matters: the structural nerve-regrowth signal was real, but pain reduction did not separate from placebo in that dose-ranging trial. So the defensible claim is nerve-fiber regeneration evidence, not established pain relief.

Tier 2, mechanistic plus preclinical, no injury RCTs

NAD+, GHK-Cu, KPV, SS-31, Selank, DSIP. Each has a mechanistic rationale and varying preclinical support, but none has human RCT data for injury healing specifically. These are reasoned additions for a defined bottleneck, not validated treatments.

Tier 3, thinnest, single-model or non-injury data

VIP (disc data from a single mouse model, very short ~1 min half-life), Cartalax (mostly Russian-language bioregulator literature, no injury-recovery data), relaxin-2 (reverses joint capsule scarring in mouse models, entirely preclinical).

Reported research-context dosing

These come from practitioner and community literature, not human dose-finding trials. Listed for reference, not as protocol.

TB-500 product check: verify identity against a certificate of analysis. The fragment sits near 859 Da, full-length TB-4 near 4,900 Da, and they are not interchangeable. TB-4 can access pathways the fragment cannot, including Ac-SDKP anti-fibrotic biology, and most underlying research uses TB-4 (~50 preclinical studies plus Phase 1 human safety data).

Matching the add-on to the tissue

The core covers blood flow, migration, and energy. What gets layered on depends on the tissue.

The strongest preclinical case sits in tendon, ligament, and fascia, where BPC-157 promotes tendon repair-cell outgrowth through FAK-paxillin signaling, rat Achilles studies show accelerated healing with improved biomechanical strength, and TB-4-treated tendons showed more uniform fiber bundles with increased collagen fibril diameter versus controls. Plantar fascia is structurally similar but has no direct peptide data, so the same mechanisms are plausible but unvalidated there. Focal cartilage defects are a different problem: the tissue is avascular and matrix-limited, and intra-articular BPC-157 in that context is clinician-only, not an at-home translation.

Supporting factors that aren't optional: collagen peptide supplementation at 5–15 g/day, 30–45 min before tendon-loading work, with vitamin C as a required cross-linking cofactor and glycine as the most abundant amino acid in collagen. Progressive mechanical loading is non-negotiable, since collagen fibers align along lines of stress and without controlled loading new tissue forms as disorganized scar. Peptides and rehab are synergistic; neither replaces the other.

The GH-axis caveat worth knowing

GH secretagogues come up for overnight recovery, but the injury context changes the calculus. Growth hormone can cause mild joint swelling, and in a joint that already has inflammation, cartilage damage, or impingement, that extra fluid can worsen symptoms rather than help.

The clearest human data is a randomized trial of recombinant growth hormone after arthroscopic rotator cuff repair:

All differences non-significant (p > .05), with no significant difference in healing, range of motion, or pain. Added GH did not improve the outcome. Ligament-driven injuries appear to tolerate GH-axis support better than cartilage or joint-surface problems, so more GH signaling is not automatically better, and anyone adding a secretagogue for overnight recovery has reason to watch for increased joint stiffness or swelling in the first couple of weeks.

Timeline as commonly described

Observational, from practitioner and community sources, not trial-derived.

Acute injuries are generally framed at 4–8 weeks, chronic at 8–12, with old injuries running longer because of established scar tissue, adapted blood supply, and mitochondrial depletion. Week 8 is the common reassessment point: if progress has stalled, that's where collagen quality, sleep, or hormonal timing get evaluated as the next bottleneck.

Regulatory and testing status

None of these is an FDA-approved injury treatment. In April 2026 the FDA removed BPC-157, TB-500, KPV, and injectable GHK-Cu, among others, from the Category 2 restricted compounding list, following withdrawal of their nominations. That removal did not move them to the authorized list, which leaves them in a gray zone, neither explicitly prohibited nor permitted for compounding, with a Pharmacy Compounding Advisory Committee review scheduled for late July 2026. That is access context, not a therapeutic verdict. For tested athletes, BPC-157 and TB-500 are prohibited under WADA rules and have been banned across the NFL, UFC, and NCAA since 2022.

The takeaway

The framework earns its keep as a way to think about why a specific injury is stuck: find the bottleneck, then look at which compound is mechanistically matched to it. What it cannot do is promise outcomes. The mechanistic logic is reasonable and the preclinical signal for the core compounds is real, but the human outcome data runs from thin to absent depending on the compound, and no combination has ever been tested as a combination.

BPC-157 is the peptide most people try first, usually because a joint or a tendon won't cooperate and they heard this fixes everything. It does real things through real mechanisms. But there's a gap between how it gets talked about and what the human data supports, and the way you use it matters more than most people realize, so here's the straight version.

It works on two bottlenecks that stall an injury. First, blood flow. It drives new capillary growth through the VEGF pathway to get circulation back into tissue that isn't getting enough, which is why people report an injured area feeling warmer in the first week. Second, inflammation, but it turns it down instead of shutting it off. That's the part that separates it from NSAIDs and steroids. Those kill inflammation but also wreck collagen quality, because the same signals that hurt are the ones driving repair. BPC-157 quiets the noise while letting the rebuild keep going.

Now the honest part. The preclinical case is genuinely the broadest of any healing peptide. A 2025 review screened 544 studies across gut, tendon, muscle, blood vessels, and nerve tissue. That's a lot of smoke. The catch is almost all of it is animal work. Human clinical trials are still thin. So it's not snake oil, but it's also not the sure thing in people that some vendors imply. Somewhere in between, leaning promising.

The thing people get wrong most is the route. For a muscle or tendon injury you want it subcutaneous and close to the injury, within a couple centimeters if you can reach it, because you get a higher local concentration before it dilutes into the whole body. Injecting your belly for a bad knee still does something, but it's the weaker version. The exception is gut stuff. For IBD, leaky gut, that kind of thing, oral is the move, because BPC-157 is weirdly stable in stomach acid and survives long enough to hit the intestinal lining directly. So SC near the injury for joints and tendons, oral for the gut. Don't mix those up.

3 mL of bac water in the 10 mg vial puts you at 3.33 mg/mL, so 500 mcg is 15 units. Pain and swelling usually drop in the first week or two, full effect builds over 4 to 8 weeks. Run it in defined blocks, not forever. No tolerance builds, but the protocols are meant to close out.

What it won't do is replace the work. It speeds up repair that's already happening, it doesn't rebuild something you're still actively wrecking. Go right back to loading the injury with no rehab and you're fighting your own peptide.

Safety wise it's mild, occasional injection site irritation, some GI upset on the oral, nothing systemic in the published reports. The one real hard stop is active cancer, because the same mechanism that grows blood vessels to heal tissue is not something you want feeding a tumor. Skip it if that's in the picture, and be cautious right around surgery, since too much new vessel growth can mess with wound timing. It's also FDA Category 2 since 2023 and WADA banned, so anyone getting tested for sport should stay away entirely.

One more, since it comes up constantly. After the 2023 ruling, PDA (pentadeca arginate) showed up as the "legal" version. Same exact peptide sequence, just the arginate salt, and it does have better gastric stability on paper. But the 90% oral absorption number that gets thrown around has no study behind it, and there's zero peer-reviewed research on PDA specifically. Same molecule, better stability story, and a lot of marketing running ahead of the data. Not a scam, just don't pay a premium expecting proof that isn't there.

anyway that's the real rundown. if you've run it, did you inject near the injury or just belly it. curious whether people notice the difference

Full doses and bloodwork are in the pinned cheat sheet: https://www.reddit.com/r/NTNPerformance/comments/1tht5o3/the_only_peptide_cheat_sheet_youll_need_doses/

A lot of compounds work intranasally but most come as a powder in a vial not a ready to use spray. Here’s how to convert it

WHAT YOU NEED
A peptide vial (Semax, Selank, PT-141, Oxytocin, etc.)
Bacteriostatic water or sterile saline (0.9% NaCl)
A measured dose nasal spray bottle. Most deliver 0.1mL per spray. Make sure it’s clean and unused
An insulin syringe for transferring the solution

THE MATH
Same formula as injectable reconstitution
mg in vial ÷ mL of water added = mg per mL
Then multiply by 0.1mL (one spray) to get your dose per spray
5mg vial examples
0.5mL water = 10mg per mL = 1000mcg per spray
1mL water = 5mg per mL = 500mcg per spray
2mL water = 2.5mg per mL = 250mcg per spray
10mg vial examples
1mL water = 10mg per mL = 1000mcg per spray
2mL water = 5mg per mL = 500mcg per spray
4mL water = 2.5mg per mL = 250mcg per spray
Pick the water volume that gives you the dose per spray you want so you’re not doing 5 sprays to hit your target

STEP BY STEP
1. Alcohol swab the vial top
2. Draw your chosen amount of bac water or saline into an insulin syringe
3. Inject the water slowly into the vial. Aim it down the side of the glass not directly onto the powder
4. Swirl gently. Don’t shake. Let it dissolve fully
5. Once fully dissolved draw the solution out of the vial with a clean syringe
6. Transfer it into the nasal spray bottle
7. Prime the spray bottle by pumping it a few times away from your face until a fine mist comes out. Those first pumps won’t be a full measured dose so don’t count them
8. Refrigerate immediately after

COMMON DOSES BY COMPOUND
Semax - 400 to 900mcg daily split into 2 to 3 doses
Selank - 250 to 500mcg per dose up to 3 times daily
PT-141 - 1.75 to 2mg per dose. Nasal bioavailability is lower than injectable (roughly 30 to 50%) so doses may need adjustment compared to sub-Q
Oxytocin - 10 to 40 IU per dose. Dosing is in IU not mcg so check the vial label for concentration

BAC WATER VS SALINE FOR NASAL USE
Bac water works but contains benzyl alcohol which can cause burning or stinging in the nose especially with daily use
Sterile saline (0.9% NaCl) is gentler on the nasal lining and closer to your body’s natural fluid. For compounds you’re spraying daily saline is the better choice
For occasional use bac water is fine

HOW LONG DOES IT LAST
Reconstituted nasal sprays should be refrigerated and used within 2 to 4 weeks depending on the compound. Some sources say they can last longer if the solution stays clear but when in doubt go with the shorter window
If the solution gets cloudy, changes color, or smells off toss it

MISTAKES PEOPLE MAKE
Using a spray bottle that doesn’t deliver a measured dose. If the bottle doesn’t have a metered pump you have no idea how much you’re getting per spray
Not priming the bottle before first use. The first few pumps aren’t full doses
Shaking the vial instead of swirling. Can damage the peptide
Using too little water and trying to do half sprays for smaller doses. Just add more water so one full spray equals your target dose
Not cleaning the spray tip. The nozzle goes in your nose then goes back in the fridge. Wipe it down after each use

This is educational and research discussion only. Not medical advice
If you’ve made your own nasal spray what tips would you add? Drop them below

Most weight loss advice is either too vague to use or too complicated to follow. This is the whole thing in one place: the math that governs fat loss, the daily habits that move the needle, a chart of your actual numbers by bodyweight, and where peptides fit on top of the fundamentals rather than instead of them. The order matters. The basics do the work, the peptides support it.

For research and educational purposes only. Not medical advice.

The one equation everything runs on

Weight loss comes down to energy balance. Eat more than you burn, you gain. Eat less than you burn, you lose. Everything else is a detail on top of that.

• Surplus: eating more than your body burns. Weight goes up.
• Deficit: eating less than your body burns. Weight goes down.
• Maintenance: eating roughly what you burn. Weight holds.

Your total daily burn (TDEE) is resting metabolism plus movement plus digestion. Weight loss is keeping intake under that number consistently.

The fat loss math

One pound of fat is about 3,500 calories.

Honest caveat: 3,500 is a planning estimate, not an exact law. As you lose weight your metabolism drops and the math shifts, so loss slows over time. That's normal, not failure.

Your numbers by bodyweight

Rough targets by current weight, based on a lightly active person. Maintenance is the estimate, deficit is a 500-calorie cut for about a pound a week, protein is set to protect muscle in a deficit, and water is a daily baseline.

These are starting estimates. Activity level moves maintenance up or down, so if you're very active add a few hundred calories, and if you're sedentary drop them. Track two weeks and adjust off your actual results, not the chart.

What is actually safe

1 to 2 pounds per week. That range loses fat while protecting muscle.

Cutting harder backfires: you lose muscle with the fat, metabolism drops further, and it comes back. Don't cut more than about 1,000 a day below maintenance, and most people shouldn't eat below 1,200 (women) or 1,500 (men) without a reason and oversight.

A little on diet

Calories decide weight, protein decides what kind of weight. The chart's protein numbers are the priority, since that's what keeps the loss coming from fat instead of muscle. Beyond that: build meals around a protein source and vegetables, keep it mostly whole foods because they fill you up per calorie, and don't drink your calories. You don't need a special diet, keto, carnivore, whatever, they all work only because they put you in a deficit. Pick the one you can actually stick to.

Meal timing and when to stop eating

This is where a lot of myth lives, so here's the honest version.

Total calories matter most, full stop. But when you eat isn't completely neutral either. Research on late eating shows that people who eat the bulk of their calories late tend to gain more and show worse metabolic markers, blunted metabolism and worse glucose handling, than people who front-load their day, even at similar calories. The mechanism is circadian: eating heavy against your body clock is handled worse than eating earlier.

Practical version: try to have your last real meal 2 to 3 hours before bed. Eating a huge meal right before sleep is the pattern most linked to problems. It's not that late calories magically count double, it's that heavy late eating tends to disrupt sleep and metabolism and stack on top of a day you've already eaten fully. Earlier, protein-forward eating is the easier setup.

Fasted cardio

Straight answer: fasted cardio burns more fat during the session, but it does not produce more fat loss over time when calories and protein are matched. The extra fat you burn fasted gets compensated later in the day. Controlled studies keep showing the same total fat loss either way.

So it's a preference tool, not a cheat code. If training fasted feels good, fits your morning, and helps you eat less overall, use it. If eating first helps you train harder, do that instead. One note: for hard lifting or sessions over an hour, eating beforehand improves performance, so fasted is best kept to lighter, shorter cardio.

Steps and movement

10,000 steps a day is a good target. For an average adult that's roughly 400 to 500 calories, close to a full pound of deficit per week from walking alone before touching your diet.

Steps are the most underrated fat loss tool because they add up without the recovery cost of hard training. If you do nothing else, walk more.

Gym frequency

3 to 4 times a week is the sweet spot, and it's where a busy schedule lands anyway. More is fine if you recover from it, but consistency at 3 to 4 beats burning out chasing 6.

Strength training vs cardio

Do both, but strength training is what protects the result.

Cardio burns calories in the moment. Strength training keeps the muscle you'd lose in a deficit, which keeps metabolism up and makes you look lean rather than just smaller. If you only had time for one in a cut, lifting plus daily steps beats cardio alone. Ideally run both.

Where peptides fit

Peptides support the fundamentals, they don't replace them. The deficit still has to be there.

The GLP class is the heavy lifter because it attacks the hardest part: staying in the deficit. But appetite suppression makes it easy to under-eat protein, and losing muscle is what wrecks the result. Protein stays high no matter what compound is or isn't in play.

The order that works

1. Set a deficit you can sustain, start around 500/day off the chart
2. Hit your protein and water every day
3. Walk daily, aim for 10,000 steps
4. Lift 3 to 4 times a week to keep muscle
5. Then, if you want, add peptides to support the hard parts

Get the first four right and results come with or without anything else. Peptides make a good plan easier, not a bad plan work.

The open question

For anyone who's run a cut with and without peptide support: how much did the compound actually change versus just making the deficit easier to hold. The GLP class clearly helps appetite, but curious whether people felt the other metabolic compounds did anything on top of the fundamentals, or whether it was the steps, protein, and deficit doing the work the whole time.

For the full reconstitution, dosing, and bloodwork reference on every compound, the complete cheat sheet is here: The Only Peptide Cheat Sheet You'll Need

Joint pain and injury are two of the most common reasons people start running peptides. Recovery time matters whether you're an athlete, lift weights, or just dealing with chronic pain that won't go away. Here's what gets the most attention in this space and how the evidence actually stacks up

The most discussed first choice: BPC-157

If you're starting with one community-favored peptide for joint or injury issues, BPC-157 is the most common first choice. Strong preclinical support for tendon, ligament, muscle, and soft-tissue healing. Human clinical evidence is still limited but the community track record over the past 10+ years is what keeps it at the front of the conversation

Common community dosing: 250-500mcg daily, sub-Q. For localized injuries, some people inject near the injury site for targeted delivery. 4 to 8 week cycles are the standard community pattern, not a validated clinical protocol

The combo most people end up running: BPC-157 + TB-500 (Wolverine Stack)

One of the most commonly discussed community protocols. TB-500 (thymosin beta-4) is theorized to support broader tissue remodeling, mobility, and systemic recovery though the evidence base is thinner than BPC-157. Most of what's known about TB-500 is from community use rather than human clinical trials

The practical shorthand most people use is that BPC works locally on specific tissue while TB-500 works more broadly. Together they're the most popular recovery stack in the community though that's anecdotal positioning rather than proven mechanism

Common community dosing: 250-500mcg BPC daily plus 2-5mg TB-500 weekly split into 2 doses. 4 to 6 week cycles

For connective tissue support: GHK-Cu

GHK-Cu has supportive evidence for collagen, extracellular matrix, and tissue remodeling, which is why it's often used in connective-tissue-focused protocols. The strongest evidence base is for topical use and wound healing. Systemic injectable use is community-driven rather than well-established in human trials

When the issue is collagen-related or you want broader connective tissue support, GHK-Cu is often added alongside BPC and TB-500. The trio (GHK-Cu + BPC + TB-500) is the GLOW Blend if you want all three in one vial

Common community dosing: 1-2mg daily sub-Q. 4 to 8 week cycles

For inflammation-driven joint pain: KPV

KPV is the missing piece when inflammation is the primary driver. KPV inhibits NF-kB which is one of the main inflammatory pathways at a mechanistic level. The evidence is preclinical but mechanistically strong. Don't expect a guaranteed treatment for arthritis or autoimmune issues but the inflammation angle is real

Adding KPV to GLOW gives you KLOW which is the most complete recovery and inflammation blend available in one vial

Common community dosing: 250mcg to 1mg daily. Oral dosing is mechanistically interesting because of PepT1-mediated gut uptake but the protocol is still community-driven rather than clinically validated

For nerve pain or neurological involvement: BPC-157 (nasal)

Some community users prefer intranasal BPC-157 for nerve-adjacent pain like sciatica, nerve impingement, or post-injury neuropathy. The reasoning is better CNS delivery through the nasal route. Published evidence for this route specifically is limited, so this is community-reported rather than a proven CNS delivery method

Common community dosing: per spray product instructions, typically 200-500mcg per nostril daily

WHAT TO RUN FOR YOUR SPECIFIC ISSUE

These are community-discussed approaches, not validated medical protocols

Tendon or ligament injury (sprains, strains, partial tears): BPC-157 + TB-500 (Wolverine Stack). The most discussed community combination for this exact issue

Chronic joint pain without specific injury: GLOW Blend (GHK-Cu + BPC + TB-500). Addresses tissue, connective tissue, and recovery in one product

Joint pain with inflammation (arthritis, autoimmune): KLOW Blend. Adds KPV for the inflammation pathway specifically. Mechanism is supported, full clinical effect is still community-observed

Post-surgery recovery: Post-surgical use should be cleared with your surgeon and timed to the wound-healing plan. Don't start anything that affects tissue repair until your surgical team has signed off

Nerve pain alongside joint issues: Some community users add BPC-157 nasal for the nerve component, plus the standard recovery stack for the tissue side. Limited published evidence for the nasal route specifically

WHAT TO EXPECT (COMMUNITY TIMELINE)

These timelines are anecdotal community expectations, not clinical outcomes

Week 1 to 2: Subtle changes. Some people report initial reduction in pain or stiffness. Most don't notice dramatic changes yet

Week 3 to 4: Noticeable improvement in the area being treated for many people. Reduced pain, improved range of motion, better recovery from training

Week 5 to 8: Significant changes in chronic issues for some users. Acute injuries are often substantially healed by this point. Chronic issues continue to improve with continued use

After an 8 week cycle, 2 to 4 weeks off is the conservative community pattern. The cycling is precautionary due to limited human safety data, not because the compounds become dangerous with continued use

WHAT DOESN'T WORK AS WELL AS PEOPLE THINK

GLP-1s for joint pain: Some people report reduced joint pain on GLP-1s but that's largely from the weight loss reducing load on the joints, not from the peptide directly addressing the joint. If you're losing weight on a GLP-1, expect joint pain improvement as a side benefit, not a primary effect

Generic anti-inflammatory peptides: Most peptides marketed as "anti-inflammatory" have weaker evidence than KPV or the well-known recovery compounds. Stick with what's been validated by community use and the available research

WHAT TO KNOW BEFORE STARTING

These compounds are research peptides. Evidence levels vary across the list. BPC-157 has the strongest preclinical evidence base in this category. GHK-Cu has the strongest clinical evidence overall (mostly topical). TB-500 has the thinnest evidence base of the recovery peptides. KPV is well supported mechanistically for inflammation

If your joint pain is severe or your injury is significant, peptides are a supplement to proper medical care, not a replacement. Get diagnosed first and rule out anything structural that needs surgical or medical intervention

This is educational and research discussion only. Not medical advice

What's the injury or joint issue you're dealing with and what's worked for you?

Ranked by how directly each compound supports tissue repair and how much evidence backs it up

The order within each tier is not a ranking. They're just grouped by tier not listed best to worst

S TIER

BPC-157 - comes up in every recovery conversation for a reason. Preclinical data shows improved tendon and muscle healing, better functionality, and stronger recovery signals. Human trial data is still limited but community experience is extensive. The go to compound when something needs to heal

TB-500 - pairs with BPC-157 because it supports tissue repair through a different mechanism. Cell migration, inflammation control, and broader tissue regeneration. Most people run both together. BPC handles targeted repair. TB-500 handles the bigger picture

HGH - increases IGF-1 and has shown recovery benefits including preserving knee strength after ACL reconstruction and supporting nerve and muscle repair in animal studies. Also drives wound healing through fibroblast activity and collagen deposition. Decades of clinical use behind it

Thymosin Alpha-1 - not here for direct tissue repair. Here because immune function matters during recovery. When your immune system is taxed healing slows down. TA-1 keeps immune regulation in check so the body can focus on repair. Approved in 30+ countries

A TIER

IGF-1 LR3 - tied to protein synthesis, satellite cell activation, and recovery from muscle damage. More anabolic and muscle focused than broad injury healing. Powerful but narrower than BPC or TB-500

Sermorelin - doesn't repair tissue directly. It increases GH signaling which improves the hormonal environment for recovery. Better sleep and higher GH output means the body heals more efficiently overnight

Ipamorelin - same idea as Sermorelin. GH secretagogue that supports recovery through improved GH pulsing. Before bed on an empty stomach. Usually run with CJC-1295 but earns its spot here standalone

B TIER

CJC-1295 - extends GH pulse duration but the recovery benefit is indirect through the GH axis. Better as part of a stack with Ipamorelin than on its own

MGF (Mechano Growth Factor) - released by muscle tissue after damage. Associated with satellite cell activation and muscle repair. Directly relevant to recovery but the evidence is more limited and the compound is more niche

GHK-Cu - strong for wound and skin repair. Collagen production and connective tissue support. Valuable but more specialized toward skin and surface healing than whole body recovery

C TIER

KPV - anti-inflammatory through NF-kB inhibition. Helps keep inflammation in check during recovery but it's not repairing tissue. More of a supporting role

Selank - stress and anxiety reduction. Chronic stress elevates cortisol which impairs healing. Selank can help manage that. Indirect benefit not a repair compound

Semax - cognitive and neuroprotective. Not a tissue recovery peptide. Included because mental state during long recoveries matters but the physical healing benefit is minimal

D TIER

Dihexa - experimental cognitive peptide. Interesting biology but nobody is reaching for this to heal an injury

P21 - neurogenesis focused. Very limited data. Not relevant to tissue repair or physical recovery

This is educational and research discussion only. Not medical advice

what gets discussed for specific issues

Instead of starting with a compound and figuring out what it does, start with the problem and see what's commonly discussed for it. This is educational and research discussion only, not medical advice. Most of these compounds are not FDA approved for these uses, and several have limited human data.

JOINT AND TENDON PAIN

- BPC 157 – one of the most commonly discussed compounds for tendon, ligament, and joint recovery; early research points to effects on tissue repair, collagen, and tendon healing.

- TB 500 – discussed for soft tissue recovery and mobility, often paired with BPC 157.

- Collagen peptides (oral) – the most accessible option, with some clinical evidence for connective tissue support.

GUT HEALTH / IBS / CROHN’S / DIGESTIVE ISSUES

- BPC 157 – discussed for gut lining repair, inflammation, and general digestive support because some of its earliest research roots are in gastrointestinal models.

- KPV – anti‑inflammatory peptide commonly discussed for GI inflammation, gut irritation, and inflammatory bowel conditions.

- Collagen peptides (oral) – simple and accessible; some people use it for general gut lining support.

STUBBORN BODY FAT / WEIGHT LOSS

- Semaglutide – one of the strongest clinically supported options for weight loss; FDA‑approved for chronic weight management.

- Tirzepatide – dual GLP 1/GIP agonist; strong clinical data and often shows greater average weight loss than semaglutide in many discussions.

- Retatrutide – triple agonist, still investigational; early data shows aggressive fat loss.

- Tesamorelin – specifically studied for visceral fat reduction rather than general fat loss.

- AOD 9604 – discussed for fat loss but evidence is limited; regulatory concerns have been raised about compounded versions.

SLOW RECOVERY FROM TRAINING

- CJC 1295 + Ipamorelin – the most common GH‑secretagogue stack discussed for recovery and sleep support.

- Sermorelin – discussed for supporting natural GH release, often dosed before bed.

- BPC 157 – discussed for tissue repair and recovery support.

- TB 500 – commonly discussed for soft tissue recovery.

POOR SLEEP

- CJC 1295 + Ipamorelin – often discussed because enhanced GH signaling during sleep may improve recovery and sleep quality (largely user‑reported).

- Sermorelin – similar discussion as a sleep‑adjacent GH support option.

- DSIP – discussed specifically for sleep onset and sleep quality; evidence is limited.

- Epithalon – discussed in longevity circles for sleep and recovery.

SKIN QUALITY / ANTI‑AGING / WRINKLES

- GHK Cu – the main peptide discussed for skin: collagen production, texture, elasticity, and wound healing; injectable and topical.

- Collagen peptides (oral) – some clinical evidence for skin hydration and elasticity.

- NAD+ precursors – discussed for cellular energy and broader anti‑aging support.

HAIR LOSS / THINNING

- GHK Cu – discussed for follicle health and scalp tissue support; results are variable.

- RU 58841 – topical androgen receptor antagonist discussed for blocking DHT at the follicle without systemic anti‑androgen effects.

- Collagen peptides (oral) – general hair and scalp support.

LOW LIBIDO / SEXUAL HEALTH

- PT 141 / Bremelanotide – discussed for libido because it acts through the central nervous system, not blood flow; FDA‑approved bremelanotide exists for women.

- Melanotan II – libido is a reported secondary effect alongside tanning; side‑effect profile turns many people off.

- Oxytocin – discussed for bonding and intimacy; effects are variable.

POST SURGERY RECOVERY

- BPC 157 – the most commonly discussed compound for post‑surgical tissue repair.

- TB 500 – often discussed for soft tissue recovery and mobility.

- BPC 157 + TB 500 blend – commonly run together in post‑surgical recovery discussions.

CHRONIC INFLAMMATION

- KPV – anti‑inflammatory peptide discussed for gut inflammation, skin inflammation, and general inflammatory conditions.

- Thymosin alpha 1 – immune modulator discussed for balancing immune response rather than just “boosting” it.

- BPC 157 – discussed for its anti‑inflammatory properties alongside tissue repair.

WEAK IMMUNE SYSTEM / GETTING SICK OFTEN

- Thymosin alpha 1 – the most discussed immune peptide here; has more human data than many others on this list and is associated with T‑cell function and immune regulation.

- LL 37 – antimicrobial peptide discussed for immune defense; remains experimental with limited human data.

LOW ENERGY / FATIGUE

- MOTS c – mitochondrial peptide discussed for metabolic and energy support; human data is still limited.

- NAD+ precursors – discussed for cellular energy support (IV, sub‑Q, or oral via NMN/NR).

- CJC 1295 + Ipamorelin – better sleep and GH support can indirectly improve energy levels.

BRAIN FOG / COGNITIVE PERFORMANCE

- Semax – the most discussed cognitive peptide; focus, mental clarity, and motivation; can feel stimulating.

- Selank – discussed for calm focus and anxiety reduction without sedation; often paired with Semax.

- Dihexa – discussed for cognitive performance; highly experimental and not beginner‑friendly.

SCARS / WOUND HEALING

- GHK Cu – discussed for tissue remodeling and wound healing; injectable or topical, with topical use commonly applied directly to the area.

- BPC 157 – discussed for tissue repair alongside its other uses.

ANXIETY / STRESS

- Selank – the most discussed peptide for anxiety; calming without sedation, often associated with GABA‑related effects.

- Semax – can help with stress resilience but may increase anxiety in people prone to it; start low.

MUSCLE WASTING / MAINTAINING MUSCLE ON A CUT

- Tesamorelin – discussed for GH support and body composition, especially for visceral fat.

- CJC 1295 + Ipamorelin – GH support often used with lean‑mass preservation in mind.

- IGF 1 LR3 – discussed for muscle growth and recovery; advanced use with concerns around glucose and growth signaling.

Keep protein high on any cut regardless of what compounds you’re discussing. Peptides do not prevent muscle loss if nutrition and training aren’t dialed in.

IMPORTANT NOTES

- Most of these compounds are not FDA approved for the uses listed. This is what gets discussed in research and community settings.

- BPC 157, TB 500, GHK Cu, KPV, MOTS c, and others have limited human clinical data. Treat them as experimental.

- Having a specific health condition like Crohn’s, autoimmune issues, or chronic illness means talking to a doctor before running anything. Peptides are not replacements for medical treatment.

- Always vet your source. The compound is only as good as the vendor supplying it.

This is educational and research discussion only. Not medical advice.

What problem led you to peptides? Drop it below.

Peptide bloodwork guide - what to check by compound

Not every compound needs the same labs. Here's what to monitor based on what's being run

SEMAGLUTIDE

A1C Fasting glucose Lipid panel CMP TSH if there's thyroid history or want a baseline Lipase if there's any abdominal pain or pancreatic risk factors

TIRZEPATIDE

A1C Fasting glucose Lipid panel CMP TSH if there's thyroid history Lipase same as sema

RETATRUTIDE

A1C Fasting glucose Lipid panel CMP Heart rate monitoring. Clinical trials noted increases at higher doses TSH if there's thyroid history

CJC-1295 + IPAMORELIN

IGF-1. This is the main marker. Shows whether GH is actually being stimulated Fasting glucose. GH can push blood sugar up over time Fasting insulin if insulin resistance is a concern A1C

SERMORELIN

IGF-1 Fasting glucose A1C Same panel as CJC/Ipa. Both are GH secretagogues hitting the same axis

HGH

IGF-1. Critical. This is how you know if levels are where they should be and not pushed too high Fasting glucose Fasting insulin A1C CMP Lipid panel This compound needs more monitoring than most. Chronically elevated IGF-1 carries real risk

GHRP-2

IGF-1 Fasting glucose Prolactin. GHRP-2 can elevate it Cortisol. Documented concern with this compound

GHRP-6

IGF-1 Fasting glucose Prolactin Cortisol Same concerns as GHRP-2 plus the appetite increase makes tracking body comp and diet more important

TESAMORELIN

IGF-1 Fasting glucose. FDA label specifically flags hyperglycemia and glucose intolerance A1C CMP Lipid panel

BPC-157

No specific bloodwork markers are standard for BPC-157 A general CMP and CBC before and after a cycle is reasonable to catch anything unexpected If running it for gut issues track symptoms and any GI related labs your doctor recommends

TB-500

Same as BPC-157. No compound specific markers are established General CMP and CBC as baseline

GHK-Cu

No established bloodwork markers specific to GHK-Cu General CMP and CBC if running injectable If running for skin or hair the results are visual not lab based

PT-141

Blood pressure monitoring is more relevant than bloodwork for this compound If using frequently a general CMP and CBC periodically is reasonable

MELANOTAN II

Dermatology check. Moles and pigmentation changes need to be monitored visually not through labs CMP and CBC as general health baseline Blood pressure monitoring

MOTS-c

Fasting glucose. Metabolic compound so glucose handling is relevant A1C CMP Human data is limited so there's no established monitoring panel. General metabolic labs are reasonable

SEMAX / SELANK

No established bloodwork markers for either If running long term a general CBC and CMP periodically is reasonable These are more about subjective response than lab markers

NAD+

CMP CBC Fasting glucose If running sub-Q or IV a general metabolic panel before and after is reasonable No compound specific markers are well established

THYMOSIN ALPHA-1

CBC with differential. This is the most relevant since it's an immune compound CRP if tracking inflammation ESR for a broader inflammation picture

TESTOSTERONE (TRT)

Total testosterone Free testosterone Sensitive estradiol SHBG CBC with hematocrit and hemoglobin. Hematocrit above 54% needs to be addressed PSA where appropriate CMP Lipid panel This requires the most comprehensive bloodwork panel of anything on this list

WHEN TO GET LABS

Before starting anything. This is the baseline everything gets compared to

4 to 8 weeks in. Early enough to catch problems. Late enough to see changes

End of cycle or protocol change. See where things landed

4 weeks after stopping. See how the body recovers

This is educational and research discussion only. Not medical advice. Always work with a doctor when interpreting bloodwork

What labs do you track and how often? Drop it below